NCMD Seminar presents 'How does psilocybin work?'

We were delighted to have guest speaker, Professor Guy Goodwin, present 'How does psilocybin work?' to our NCMD seminar programme this week. This event was part of a joint Northern Centre for Mood Disorders (NCMD) and Transformative Neuroscience NUCore hybrid seminar.

Professor Goodwin, has previously held the position of President of the British Association for Psychopharmacology, President of the European College of
Neuropsychopharmacology (ECNP), and Senior Investigator on the faculty of UK National Institute for Health Research (NIHR). His research interests have been focused on the treatment of mood disorders and, increasingly, the potential to improve treatment using new technology and new drugs, notably psychedelics.
He was part of the team that developed Compass Pathways’ phase IIb clinical trial and acted initially as its coordinating principal investigator.

His seminar covered pharmacology of psilocybin, dosage, psychedelic experience as a biomarker and how we obtain approval for regulated access. He also delved deeper into the history of psilocybin research and the current evidence base.

If you are interested in finding out more about research trialling psilocybin, please see the link below to our COMP006 study.

Thank you so much to Professor Goodwin for delivering this fantastic seminar and thank you to everyone who came along to this hybrid event.